ABIVAX Société Anonyme (NASDAQ:ABVX) is among the 20 Best Performing Stocks in 2025.
According to a story in the French-language newspaper La Tribune on December 24, 2025, there have been rumors that Eli Lilly has been drawing interest in the French biotechnology business ABIVAX Société Anonyme, TheFly reported. Its shares surged after the release, rising $4.62, or 3%, to $142.97 in pre-market trade in New York.
The company also declared that it was going to be included in the Nasdaq Biotechnology Index. The inclusion went into effect on Monday, December 22, 2025.
Thefly revealed on December 18, 2025, that Guggenheim analyst Yatin Suneja has increased the company’s price objective for ABIVAX Société Anonyme from $150 to $175. The analyst maintained a Buy rating for the stock. Guggenheim’s positive forecast for obefazimod ahead of an impending 44-week maintenance readout is the basis for the price target hike.
The firm has €589.7 million in cash despite high R&D-driven losses and a €15.3 million monthly cash burn.
Nonetheless, the stock is down by 10.04% YTD as of January 6, 2026.
READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.
Disclosure. None
